Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy

Yusup S. Sutanto; Muhammad Rudiannor; Jatu Aphridasari; Hendra Kurniawan

doi:10.14710/jbtr.v10i2.20330

DOI: https://doi.org/10.14710/jbtr.v10i2.20330

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy

Yusup S. Sutanto^{1, 2} , Muhammad Rudiannor^{1, 2}, Jatu Aphridasari^{1, 2}, Hendra Kurniawan³

¹Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sebelas Maret , Indonesia

²Dr. Moewardi General Hospital, Indonesia

³Department of Public Health and Community Medicine, Faculty of Medicine, Universitas Syiah Kuala, Indonesia

Received: 30 Aug 2023; Accepted: 19 Apr 2024; Available online: 30 Aug 2023; Published: 30 Aug 2024.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to cite (IEEE): Y. S. Sutanto, M. Rudiannor, J. Aphridasari, and H. Kurniawan, "Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy," Journal of Biomedicine and Translational Research, vol. 10, no. 2, pp. 55-60, Aug. 2024. https://doi.org/10.14710/jbtr.v10i2.20330

How to cite (APA): Sutanto, Y. S., Rudiannor, M., Aphridasari, J., & Kurniawan, H. (2024). Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy. Journal of Biomedicine and Translational Research, 10(2), 55-60. https://doi.org/10.14710/jbtr.v10i2.20330

How to cite (BCREC): Sutanto, Y. S., Rudiannor, M., Aphridasari, J., Kurniawan, H. (2024). Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy. Journal of Biomedicine and Translational Research, 10 (2), 55-60 (doi:10.14710/jbtr.v10i2.20330)

How to cite (Chicago): Sutanto, Yusup S., Muhammad Rudiannor, Jatu Aphridasari, and Hendra Kurniawan. "Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy." Journal of Biomedicine and Translational Research 10, no. 2 (2024): 55-60. Accessed : April 4, 2025. https://doi.org/10.14710/jbtr.v10i2.20330

How to cite (Vancouver): Sutanto YS, Rudiannor M, Aphridasari J, Kurniawan H. Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy. Journal of Biomedicine and Translational Research [Online]. 2024 Aug;10(2):55-60. https://doi.org/10.14710/jbtr.v10i2.20330.

How to cite (Harvard): Sutanto, Y. S., Rudiannor, M., Aphridasari, J., and Kurniawan, H., 2024. Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy. Journal of Biomedicine and Translational Research, [Online] Volume 10(2), pp. 55-60. https://doi.org/10.14710/jbtr.v10i2.20330 [Accessed : 4 Apr. 2025].

How to cite (MLA8): Sutanto, Yusup S., Muhammad Rudiannor, Jatu Aphridasari, and Hendra Kurniawan. "Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy." Journal of Biomedicine and Translational Research, vol. 10, no. 2, 30 Aug. 2024, pp. 55-60 , https://doi.org/10.14710/jbtr.v10i2.20330. Retrieved : 4 Apr. 2025.

BibTex Citation Data :

@article{JBTR20330,
    author = {Yusup S. Sutanto and Muhammad Rudiannor and Jatu Aphridasari and Hendra Kurniawan},
    title = {Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy},
    journal = {Journal of Biomedicine and Translational Research},
  volume = {10},
    number = {2},
    year = {2024},
    keywords = {leukocyte; lymphocyte; lung tumor; malignancy; neutrophil; platelet.},
    abstract = {  Background : Inflammatory cells play an essential role in the neoplastic process by stimulating cancer proliferation, survival, and migration. Neutrophil-lymphocyte and platelet-lymphocyte levels can be used as the inflammatory tissue damage markers in cancer patients.   Objective : This study aimed to analyze the increase of neutrophil-lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) as the predictive factors for lung malignancy.   Methods : This study was a diagnostic cross-sectional study design in lung tumor patients at Dr. Moewardi Hospital Surakarta from August to October 2018. The subjects (60) were selected with consecutive sampling who take lung cancer diagnostic tests and divided into two groups of patients with lung tumors (30) and healthy (30) as control. The diagnostic procedures and neutrophil–lymphocyte and platelet–lymphocyte ratios calculation were performed on both groups. The optimum cutoff values for the NLR and PLR were calculated from the receiver operating curve analysis.   Results : The statistical test found a significant difference in the neutrophil–lymphocyte and platelet–lymphocyte ratios between cancer patients and control (p = 0.0000). The lung cancer group exhibited an increase in the NLR with 90.0% sensitivity and 96.7% specificity with a cutoff of 2.71. The platelet–lymphocyte ratio had a cutoff of 136.63 at 83.3% sensitivity and 80.0% specificity.   Conclusion : The increase of neutrophil-lymphocyte and the platelet-lymphocyte ratio can be used as a predictive predictor of lung malignancy. },
   issn = {2503-2178},   pages = {55--60}  doi = {10.14710/jbtr.v10i2.20330},
    url = {https://ejournal2.undip.ac.id/index.php/jbtr/article/view/20330}
}

Refworks Citation Data :

@article{{JBTR}{20330}, author = {Sutanto, Y., Rudiannor, M., Aphridasari, J., Kurniawan, H.}, title = {Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy}, journal = {Journal of Biomedicine and Translational Research}, volume = {10}, number = {2}, year = {2024}, doi = {10.14710/jbtr.v10i2.20330}, url = {https://ejournal2.undip.ac.id/index.php/jbtr/article/view/20330} }

Citation Format:

Abstract

Background: Inflammatory cells play an essential role in the neoplastic process by stimulating cancer proliferation, survival, and migration. Neutrophil-lymphocyte and platelet-lymphocyte levels can be used as the inflammatory tissue damage markers in cancer patients.

Objective: This study aimed to analyze the increase of neutrophil-lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) as the predictive factors for lung malignancy.

Methods: This study was a diagnostic cross-sectional study design in lung tumor patients at Dr. Moewardi Hospital Surakarta from August to October 2018. The subjects (60) were selected with consecutive sampling who take lung cancer diagnostic tests and divided into two groups of patients with lung tumors (30) and healthy (30) as control. The diagnostic procedures and neutrophil–lymphocyte and platelet–lymphocyte ratios calculation were performed on both groups. The optimum cutoff values for the NLR and PLR were calculated from the receiver operating curve analysis.

Results: The statistical test found a significant difference in the neutrophil–lymphocyte and platelet–lymphocyte ratios between cancer patients and control (p = 0.0000). The lung cancer group exhibited an increase in the NLR with 90.0% sensitivity and 96.7% specificity with a cutoff of 2.71. The platelet–lymphocyte ratio had a cutoff of 136.63 at 83.3% sensitivity and 80.0% specificity.

Conclusion: The increase of neutrophil-lymphocyte and the platelet-lymphocyte ratio can be used as a predictive predictor of lung malignancy.

Note: This article has supplementary file(s).

Fulltext View|Download | Cover Letter

Cover Letter

Subject
Type	Cover Letter
	Download (19KB) Indexing metadata

common.other

Suggest Reviewer

Subject
Type	Other
	Download (11KB) Indexing metadata

Keywords: leukocyte; lymphocyte; lung tumor; malignancy; neutrophil; platelet.

Article Metrics:

Article Info

Section: Original Research Articles

Language : EN

In Vol 10, No 2 (2024): August 2024

Recent articles

Revealing the Potency of Camelia sinensis and Serenoa repens as Purinoreceptor Inhibitor for Benign Prostatic Hyperplasia Treatment through in Silico Study Psychotherapy Supportive Practice For Borderline Personality Disorder (A Clinical Module Development) The Relationship Between the Duration of Kangaroo Mother Care and Edinburgh Postnatal Depression Scale Outcomes in Mothers with Preterm Infants More recent articles

Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:7S-37S. https://doi.org/10.1378/chest.12-2377
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61: 69-90. https://doi.org/10.3322/caac.20107
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29. https://doi.org/10.3322/caac.20138
Gomes M, Teixeira AL, Coelho A, Araujo A, Medeiros R. Inflammation and lung cancer oxidatives Stress, ROS, and DNA damage. In: Ahmad SI, eds. Reactive Oxygen Species in Biology and Human Health. London: CRC Press; 2016
Nikolić I, Kukulj S, Samaržija M, Jeleč V, Žarak M, Orehovec B, Taradi I, Romic D, Kolak T, Patrlj L. Neutrophil-to-lymphocytes and platelet-to-lymphocytes ratio help identify patients with lung cancer, but don't differentiate between lung cancer subtypes. Croat Med J. 2016; 57: 287–92. https://doi.org/10.3325/cmj.2016.57.287
Heron M. Deaths: Leading causes for 2013. Natl Vital Stat Rep 2016; 65 :1-94
Yoon HI, Kwon OR, Kang KN, Shin YS, Shin HS, Yeon EH, Kwon KY, Hwang I, Jeon YK, Kim Y, Kim CW. Diagnostic value of combining tumors and inflammatory markers in lung cancer. J Cancer Prev. 2016;21:187–193. https://doi.org/10.15430/JCP.2016.21.3.187
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;19(420):860-867. https://doi.org/10.1038/nature01322
Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutrophils/lymphocytes and platelets / lymphocytes rates in patients with non-small cell lung cancer associated with treatment response and prognosis?. Asian Pac J Cancer Prev. 2013;14:5237–42. https://doi.org/10.7314/apjcp.2013.14.9.5237
Karagöz B, Alacacioǧlu A, Bilgi O, Demirci H, Özgün A, Erikçi AA, Sayan O, Yilmaz B, Kandemir EG. Platelet count and platelet distribution width increases in lung cancer patients. Anatol J Clin Investig. 2009;3:32–4
Mikogami T, Kunimura T, Omatsu M, Shiokawa A, Nagai T, Hirota Y, Koji S, Ohike N, Kitami A, Suzuki T. Neutrophil-rich pulmonary carcinoma: Clinicopathological characteristicsand cytokine expression and their relationship with lymph node metastasis. Showa Univ J Med Sci. 2014;26:9-16. https://doi.org/10.15369/sujms.26.9
Aldarouish M, Wang C. Trends and advances in tumor immunology and lung cancer immunotherapy. J Exp Clin Cancer Res.2016;35:157. https://doi.org/10.1186/s13046-016-0439-3
Indonesian Ministry of Health. National Guidelines for Medical Services: Lung Cancer. Jakarta: Indonesian Ministry of Health; 2017. p. 1–75. [In Indonesia]
Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends. J Thorac Oncol, 2008;3:819–31. https://doi.org/10.1097/JTO.0b013e31818020eb
Hruba F, Fabiánová E, Bencko V, Cassidy A, Lissowska J, Mates D, Rudnai P, Zaridze D, Foretova L, Janout V, Dabrowska NS, Brennan P, Boffrtta P. Socioeconomic indicators and risk of lung cancer in central and eastern Europe. Cent Eur J Public Health. 2009;17: 115–21
Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J, 2009;34:380-386. https://doi.org/10.1183/09031936.00144208
Rahal Z, El Nemr S, Sinjab A, Chami H, Tfayli A, Kadara H. Smoking and lung cancer: A geo-regional perspective. Front Oncol. 2017;7:194. https://doi.org/10.3389/fonc.2017.00194
Zhu H, Zhang S. Body mass index and lung cancer risk in never smokers: a meta-analysis. BMC Cancer. 2018;18:635. https://doi.org/10.1186/s12885-018-4543-y
Iyer S, Roughley A, Rider A, Taylor-Stokes G. The symptom burden of non-small cell lung cancer in the USA: A real-world cross-sectional study. Support Care Cancer. 2014;22:181-7. https://doi.org/10.1007/s00520-013-1959-4
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646–74. https://doi.org/10.1016/j.cell.2011.02.013
Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010;185:2273–
https://doi.org/10.4049/jimmunol.1000901
Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer 2016;16:431–46. https://doi.org/10.1038/nrc.2016.52
Zhang X, Ran Y. Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8:5379–87
Peng B, Wang YH, Liu YM, Ma LX. Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: A systemic review and meta-analysis. Int J Clin Exp Med. 2015;8:3098-106
Kargl J, Busch SE, Yang GHY, Kim KH, Hanke ML, Metz HE, Hubbard JJ, Lee SM, Madtes DK, McIntosh MW, Houghton AM. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017;8:14381. https://doi.org/10.21037/jtd.2017.04.55
Kemal Y, Yucel I, Ekiz K, Demirag G, Yilmaz B, Teker F, Ozdemir M. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pac J Cancer Prev. 2014;15:2651-2654. https://doi.org/10.7314/apjcp.2014.15.6.2651

Last update:

No citation recorded.

Last update:

No citation recorded.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

The Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to Journal of Biomedicine and Translational Research Diponegoro University as publisher of the journal.

Copyright encompasses non-exclusive rights to reproduce and deliver the article in all form and media, including reprints, photographs, microfilms and any other similar reproductions, as well as translations.

Journal of Biomedicine and Translational Research Diponegoro University, the Editors and the Advisory International Editorial Board make every effort to ensure that no wrong or misleading data, opinions or statements be published in the journal. In any way, the contents of the articles and advertisements published in the Journal of Biomedicine and Translational Research Diponegoro University (JBTR) are sole and exclusive responsibility of their respective authors and advertisers.

The Copyright Transfer Form can be downloaded here: [Copyright Transfer Form JBTR]

The copyright form should be signed originally and send to the Editorial Office in the form of original mail, scanned document or fax :
Journal of Biomedicine and Translational Research Faculty of Medicine, Diponegoro University
Jl. Prof. Soedarto, Kampus UNDIP Tembalang, Semarang, Central Java, Indonesia 50275, Telp.: +62-24-8454714, Fax.: +62-24-8454714
Email: jbtr@fk.undip.ac.id